Zacks Investment Research on MSN

MRNA & MRK's Personalized Cancer Therapy Delivers Strong 5-Year Data

Shares of Moderna MRNA were up 15.8% on Jan. 21, after the company and its partner Merck MRK announced positive median ...

Moderna–Merck Cancer Vaccine Shows Durable Benefit At 5 Years In High-Risk Melanoma

Moderna and Merck shared five-year study data showing their combined cancer treatment cut the risk of melanoma coming back or ...
Benzinga.com

Merck's Multi-Billion Cancer Drug Keytruda Aces Late-Stage Breast Cancer Study (UPDATED)

Keytruda demonstrated statistically significant and clinically meaningful improvement in OS compared to pre-operative chemotherapy. KEYNOTE 522 is the fourth study of a Keytruda-based regimen in an ...
Seeking Alpha

Merck Phase 3 study of Winrevair in PAH meets primary endpoint

Merck (NYSE:MRK) said a pivotal Phase 3 study for its drug Winrevair in the treatment of pulmonary arterial hypertension, or PAH, has met its primary endpoint. Topline results from the study, called ...
Nasdaq

MRK Begins 2nd Phase III Study on Rare Blood Disorder Candidate

Merck MRK announced that it has initiated a phase III called Shorespan-007 study on its lysine-specific demethylase 1 (LSD1) inhibitor, bomedemstat, for the treatment of patients with essential ...